{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:53:12Z","timestamp":1779144792355,"version":"3.51.4"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:00:00Z","timestamp":1339459200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0038622","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T21:01:59Z","timestamp":1339534919000},"page":"e38622","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Effects of Valacyclovir on Markers of Disease Progression in Postpartum Women Co-Infected with HIV-1 and Herpes Simplex Virus-2"],"prefix":"10.1371","volume":"7","author":[{"given":"Alison C.","family":"Roxby","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison L.","family":"Drake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisca","family":"Ongecha-Owuor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James N.","family":"Kiarie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbra","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel N.","family":"Matemo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Overbaugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Emery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace C.","family":"John-Stewart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Wald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carey","family":"Farquhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2012,6,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/01.AOG.0000251511.27725.5c","article-title":"Herpes simplex virus type 2 and risk of intrapartum human immunodeficiency virus transmission.","volume":"109","author":"AL Drake","year":"2007","journal-title":"Obstet Gynecol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1086\/379333","article-title":"Human immunodeficiency virus acquisition associated with genital ulcer disease and herpes simplex virus type 2 infection: a nested case-control study in Rakai, Uganda.","volume":"188","author":"D Serwadda","year":"2003","journal-title":"J Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1258\/095646205774763298","article-title":"Chronic herpes simplex virus type-2 infection and HIV viral load.","volume":"16","author":"WA Duffus","year":"2005","journal-title":"Int J STD AIDS"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1097\/QAD.0b013e328010238d","article-title":"Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial.","volume":"20","author":"A Ouedraogo","year":"2006","journal-title":"AIDS"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa0904849","article-title":"Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.","volume":"362","author":"C Celum","year":"2010","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1086\/593214","article-title":"Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2\/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.","volume":"198","author":"JM Baeten","year":"2008","journal-title":"J Infect Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/QAD.0b013e32831db217","article-title":"Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2\/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa.","volume":"23","author":"S Delany","year":"2009","journal-title":"AIDS"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1086\/522523","article-title":"Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1\/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.","volume":"196","author":"RA Zuckerman","year":"2007","journal-title":"J Infect Dis"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1086\/651696","article-title":"Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: a randomized controlled trial.","volume":"201","author":"C Tanton","year":"2010","journal-title":"J Infect Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa062607","article-title":"Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.","volume":"356","author":"N Nagot","year":"2007","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/QAI.0b013e3181831832","article-title":"Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand.","volume":"49","author":"EF Dunne","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(09)62038-9","article-title":"Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.","volume":"375","author":"JR Lingappa","year":"2010","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(12)70037-3","article-title":"Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial.","author":"SJ Reynolds","year":"2012"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1093\/infdis\/jir766","article-title":"Valacyclovir suppressive therapy reduces plasma and breast milk HIV-1 RNA levels during pregnancy and postpartum: a randomized trial.","volume":"205","author":"AL Drake","year":"2011","journal-title":"J Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2006.02.006","article-title":"Clinical correlates of index values in the focus HerpeSelect ELISA for antibodies to herpes simplex virus type 2 (HSV-2).","volume":"36","author":"R Ashley Morrow","year":"2006","journal-title":"J Clin Virol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1128\/JCM.38.7.2688-2695.2000","article-title":"Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya.","volume":"38","author":"S Emery","year":"2000","journal-title":"J Clin Microbiol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1086\/597617","article-title":"Comparison of CD4 cell count, viral load, and other markers for the prediction of mortality among HIV-1-infected Kenyan pregnant women.","volume":"199","author":"ER Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e1000239","DOI":"10.1371\/journal.pmed.1000239","article-title":"Pretreatment CD4 cell slope and progression to AIDS or death in HIV-infected patients initiating antiretroviral therapy\u2013the CASCADE collaboration: a collaboration of 23 cohort studies.","volume":"7","author":"M Wolbers","year":"2010","journal-title":"PLoS Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00002030-200402200-00009","article-title":"Rate of decline of absolute number and percentage of CD4 T lymphocytes among HIV-1-infected adults in Dar es Salaam, Tanzania.","volume":"18","author":"W Urassa","year":"2004","journal-title":"AIDS"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/00002030-200501030-00016","article-title":"Slow decline in CD4 cell count in a cohort of HIV-infected adults living in Lusaka, Zambia.","volume":"19","author":"M Katubulushi","year":"2005","journal-title":"AIDS"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1093\/infdis\/jir649","article-title":"High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1\/HSV-2 coinfected persons: a randomized, crossover trial.","volume":"204","author":"K Mugwanya","year":"2011","journal-title":"J Infect Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1097\/QAD.0b013e32832aadf2","article-title":"Estimating the public health impact of the effect of herpes simplex virus suppressive therapy on plasma HIV-1 viral load.","volume":"23","author":"RF Baggaley","year":"2009","journal-title":"AIDS"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1097\/QAD.0b013e328312c756","article-title":"Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression.","volume":"22","author":"K Modjarrad","year":"2008","journal-title":"AIDS"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/OLQ.0b013e31820b8bc8","article-title":"The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa.","volume":"38","author":"P Vickerman","year":"2011","journal-title":"Sex Transm Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/infdis\/jiq013","article-title":"Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1\/HSV-2 dually infected persons.","volume":"203","author":"JM Baeten","year":"2010","journal-title":"J Infect Dis"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1128\/JCM.01263-10","article-title":"Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials.","volume":"48","author":"D Watson-Jones","year":"2010","journal-title":"J Clin Microbiol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/QAI.0b013e318229147e","article-title":"Optimal time on HAART for prevention of mother-to-child transmission of HIV.","volume":"58","author":"CJ Chibwesha","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref28","article-title":"Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach. 2010 Version.","year":"2010"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S0140-6736(10)62303-3","article-title":"Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach.","volume":"378","author":"EJ Schouten","year":"2011","journal-title":"Lancet"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"e19201","DOI":"10.1371\/journal.pone.0019201","article-title":"Factors influencing retention in care after starting antiretroviral therapy in a rural South african programme.","volume":"6","author":"TH Boyles","year":"2011","journal-title":"PLoS One"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.trstmh.2011.02.011","article-title":"Implementation and outcomes of an active defaulter tracing system for HIV, prevention of mother to child transmission of HIV (PMTCT), and TB patients in Kibera, Nairobi, Kenya.","volume":"105","author":"KA Thomson","year":"2011","journal-title":"Trans R Soc Trop Med Hyg"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0038622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:50:38Z","timestamp":1594255838000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0038622"}},"subtitle":[],"editor":[{"given":"Claire","family":"Thorne","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,6,12]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2012,6,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0038622","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,12]]}}}